Steven Wang joined Novo Ventures (US) Inc. in 2022 as a senior associate in our Boston office. Steven previously worked in corporate development at Korro Bio, an early stage RNA editing company. Prior to Korro Bio, he was on the investing team at the Dementia Discovery fund, where he invested in early stage CNS companies. Steven also spent time at L.E.K. consulting, where he worked with healthcare clients on strategy, M&A, and due diligence.
Steven holds a Ph.D. from Johns Hopkins, where he studied telomere biology, and a BA from the University of Pennsylvania.